智通财经APP讯，百利天恒(688506.SH)披露公告，关于iza-bren(EGFR×HER3双抗ADC)用于局部晚期或转移性三阴乳腺癌III期临床试验的期中分析达到主要终点的事项，该III期临床研究独立数据监查委员会(iDMC)，在预设的期中分析中，建议：“基于现有的分析结果，与监管沟通提前申报，同时继续对受试者进行随访”。
顶线(topline)数据显示iza-bren显著延长了无进展生存期(PFS)和总生存期(OS)，达到双主要终点。适应症为：治疗既往经紫杉烷类治疗失败的不可手术切除的局部晚期或转移性三阴乳腺癌。这是该双抗ADC达到主要终点的第三个III期临床研究，也是全球首个双抗ADC药物在三阴乳腺癌治疗中取得PFS/OS双阳性结果的III期临床研究(研究方案编号：BL-B01D1-307)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.